How Should Clinicians Discuss Deprescribing with Caregivers of Older Adults Living with Dementia? A Qualitative Study.

IF 3.4 3区 医学 Q2 GERIATRICS & GERONTOLOGY Drugs & Aging Pub Date : 2025-01-19 DOI:10.1007/s40266-024-01179-w
Lauren M Fasth, Casey J Kelley, Cathleen Colón-Emeric, Ariel R Green, Carolyn T Thorpe, Meredith Gilliam, Jennifer L Lund, Laura C Hanson, Joshua D Niznik
{"title":"How Should Clinicians Discuss Deprescribing with Caregivers of Older Adults Living with Dementia? A Qualitative Study.","authors":"Lauren M Fasth, Casey J Kelley, Cathleen Colón-Emeric, Ariel R Green, Carolyn T Thorpe, Meredith Gilliam, Jennifer L Lund, Laura C Hanson, Joshua D Niznik","doi":"10.1007/s40266-024-01179-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Preventive medications are potential targets for deprescribing in older adults with dementia as goals of care change from preventive to palliative. Yet, prescribers lack communication guidance to address deprescribing.</p><p><strong>Objective: </strong>Using bisphosphonates as a case example, we sought to characterize and compare communication preferences of prescribers and family/informal caregivers regarding deprescribing.</p><p><strong>Methods: </strong>We conducted 23 semi-structured interviews with prescribers (12) and caregivers (11) of older adults with Alzheimer's disease or related dementias (ADRD). Prescribers and caregivers were asked to provide their impressions of seven conversation starters for discussing deprescribing, focusing on a case example using bisphosphonates. These phrases focused on topics including life expectancy, treatment burden, adverse effects, and costs. We used a qualitative framework analysis to identify relevant themes as prescribers and caregivers discussed their general perceptions of the potential benefits and harms of bisphosphonates and experiences with deprescribing.</p><p><strong>Results: </strong>Among prescribers, there were ten physicians and two nurse practitioners; most (nine) female and white. Among caregivers, eight were female, seven were white, and five were Latino/a. For both prescribers and caregivers, preferred conversation starters initiated a risk versus benefit discussion, emphasizing medication adverse effects and patient-specific factors, such as functional status and indication for treatment. While prescribers emphasized discussing common medication adverse effects, caregivers noted the importance of knowing a medication's potential impact on ADRD. The least preferred conversation starter for deprescribing among both groups focused on the extra effort and cost of continuing bisphosphonates. Discordance between caregivers and prescribers were identified in several phrases; notably, caregivers disliked statements that introduced discussions of prognosis and life expectancy.</p><p><strong>Conclusions: </strong>Deprescribing conversations may be best perceived by caregivers when introduced with a discussion of a medication's adverse effects and potential impact on cognition. In addition, deprescribing conversations should be tailored to patient-specific factors, including functional status, goals of care, and the role of their caregiver in medical decision-making. Avoiding discussions of medication cost, pill burden, and life expectancy may help reassure the caregiver that deprescribing is a form of medication optimization and not a withdrawal of care.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs & Aging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40266-024-01179-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Preventive medications are potential targets for deprescribing in older adults with dementia as goals of care change from preventive to palliative. Yet, prescribers lack communication guidance to address deprescribing.

Objective: Using bisphosphonates as a case example, we sought to characterize and compare communication preferences of prescribers and family/informal caregivers regarding deprescribing.

Methods: We conducted 23 semi-structured interviews with prescribers (12) and caregivers (11) of older adults with Alzheimer's disease or related dementias (ADRD). Prescribers and caregivers were asked to provide their impressions of seven conversation starters for discussing deprescribing, focusing on a case example using bisphosphonates. These phrases focused on topics including life expectancy, treatment burden, adverse effects, and costs. We used a qualitative framework analysis to identify relevant themes as prescribers and caregivers discussed their general perceptions of the potential benefits and harms of bisphosphonates and experiences with deprescribing.

Results: Among prescribers, there were ten physicians and two nurse practitioners; most (nine) female and white. Among caregivers, eight were female, seven were white, and five were Latino/a. For both prescribers and caregivers, preferred conversation starters initiated a risk versus benefit discussion, emphasizing medication adverse effects and patient-specific factors, such as functional status and indication for treatment. While prescribers emphasized discussing common medication adverse effects, caregivers noted the importance of knowing a medication's potential impact on ADRD. The least preferred conversation starter for deprescribing among both groups focused on the extra effort and cost of continuing bisphosphonates. Discordance between caregivers and prescribers were identified in several phrases; notably, caregivers disliked statements that introduced discussions of prognosis and life expectancy.

Conclusions: Deprescribing conversations may be best perceived by caregivers when introduced with a discussion of a medication's adverse effects and potential impact on cognition. In addition, deprescribing conversations should be tailored to patient-specific factors, including functional status, goals of care, and the role of their caregiver in medical decision-making. Avoiding discussions of medication cost, pill burden, and life expectancy may help reassure the caregiver that deprescribing is a form of medication optimization and not a withdrawal of care.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
临床医生应该如何与老年痴呆症患者的护理人员讨论开处方?定性研究。
背景:预防药物是老年痴呆症患者处方减少的潜在目标,因为护理目标从预防性到姑息性转变。然而,开处方者缺乏沟通指导来解决处方解方问题。目的:以双膦酸盐为例,我们试图描述和比较处方者和家庭/非正式护理者关于处方的沟通偏好。方法:我们对老年阿尔茨海默病或相关痴呆(ADRD)的处方者(12人)和护理者(11人)进行了23次半结构化访谈。开处方者和护理人员被要求提供他们对讨论处方解除的七个对话启动者的印象,重点是使用双磷酸盐的一个案例。这些短语关注的主题包括预期寿命、治疗负担、副作用和费用。我们使用定性框架分析来确定相关主题,因为处方者和护理者讨论了他们对双膦酸盐的潜在益处和危害的一般看法以及减少处方的经验。结果:开处方者中医师10人,执业护士2人;大多数(9只)是雌性和白色的。在护理人员中,8名是女性,7名是白人,5名是拉丁裔。对于开处方者和护理者来说,首选的谈话开场白会引发风险与收益的讨论,强调药物的不良反应和患者的特定因素,如功能状态和治疗的适应症。处方医生强调讨论常见的药物不良反应,而护理人员则强调了解药物对ADRD的潜在影响的重要性。两组人中最不喜欢的开场白是继续使用双磷酸盐的额外努力和成本。护理人员和处方者之间的不一致在几个短语中被确定;值得注意的是,护理人员不喜欢讨论预后和预期寿命的声明。结论:当讨论药物的副作用和对认知的潜在影响时,护理人员可能会最好地理解处方对话。此外,描述对话应根据患者的具体因素进行调整,包括功能状态、护理目标和护理人员在医疗决策中的角色。避免讨论药物费用、药丸负担和预期寿命可能有助于使护理人员确信,开处方是药物优化的一种形式,而不是放弃治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Drugs & Aging
Drugs & Aging 医学-老年医学
CiteScore
5.50
自引率
7.10%
发文量
68
审稿时长
6-12 weeks
期刊介绍: Drugs & Aging delivers essential information on the most important aspects of drug therapy to professionals involved in the care of the elderly. The journal addresses in a timely way the major issues relating to drug therapy in older adults including: the management of specific diseases, particularly those associated with aging, age-related physiological changes impacting drug therapy, drug utilization and prescribing in the elderly, polypharmacy and drug interactions.
期刊最新文献
Regular Use of Oral Nonsteroidal Anti-inflammatory Drugs in a Population of Polish Seniors: Findings from the PolSenior2 Cross-Sectional Survey. Psychotropic Polypharmacy in Dementia: A Retrospective Analysis for People with Neuropsychiatric Symptoms Referred to an Australian Dementia Support Service. An Educational Intervention to Promote Central Nervous System-Active Deprescribing in Dementia: A Pilot Study. How Should Clinicians Discuss Deprescribing with Caregivers of Older Adults Living with Dementia? A Qualitative Study. Pharmacologic Management of Heart Failure with Preserved Ejection Fraction (HFpEF) in Older Adults.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1